Wilna Liebenberg

Prof. Dr. Wilna Liebenberg


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
BDBharathi Devarakonda
Bharathi Devarakonda
RHRonald A. Hill
Ronald A. Hill
WLWilna Liebenberg
Wilna Liebenberg
MBMarius Brits
Marius Brits
MVMelgardt M. de Villiers
Melgardt M. de Villiers

1 January 2001 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SHStanley Q. Henwood
Stanley Q. Henwood
WLWilna Liebenberg
Wilna Liebenberg
LTLourens R. Tiedt
Lourens R. Tiedt
ALAntonie P. Lötter
Antonie P. Lötter
MVMelgardt M. de Villiers
Melgardt M. de Villiers
(2001). Characterization of the Solubility and Dissolution Properties of Several New Rifampicin Polymorphs, Solvates, and Hydrates. Drug Development and Industrial Pharmacy: Vol. 27, No. 10, pp. 1017-1030.

1 January 2004 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ETElsa C. van Tonder
Elsa C. van Tonder
TMTshoane S.P. Maleka
Tshoane S.P. Maleka
WLWilna Liebenberg
Wilna Liebenberg
MSMingna Song
Mingna Song
DWDale Eric Wurster
Dale Eric Wurster
MVMelgardt M. de Villiers
Melgardt M. de Villiers

1 January 2013 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SSSchalk J. Strydom
Schalk J. Strydom
WRWarren E. Rose
Warren E. Rose
Daniel P OttoDaniel P Otto
Daniel P Otto
WLWilna Liebenberg
Wilna Liebenberg
MVMelgardt De Villiers
Melgardt De Villiers

1 February 2007 in Thermochimica Acta
Verified
Journal Article
Closed access
DGD. Grooff
D. Grooff
MVMelgardt De Villiers
Melgardt De Villiers
WLWilna Liebenberg
Wilna Liebenberg

1 January 2000 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SHS. Q. Henwood
S. Q. Henwood
MVM. M. de Villiers
M. M. de Villiers
WLWilna Liebenberg
Wilna Liebenberg
ALA. P. Lötter
A. P. Lötter
Rifampicin shows polymorphism; therefore, it is necessary to select a suitable crystal form at an early stage of development to ensure optimum solubility and dissolution rates. This study was an investigation into the crystal properties of several rifampicin raw materials currently being used by manufacturers of generic rifampicin raw materials in South Africa. Powders were characterized by X-ray diffraction (XRD), infrared (IR) spectroscopy, and differential scanning calorimetry (DSC). The solubility in water and dissolution properties in water, buffer pH 7.4 and 0.1 M HCl, were also measured. The main difference between the powders was the amorphous content. XRD, IR, and DSC methods could detect the presence of amorphous rifampicin. In contrast to expectations, an increase in amorphous content significantly reduced the dissolution rate of the powders in water and buffer pH 7.4. This behavior was attributed to the electrostatic properties of the very fine particles in the amorphous powders. The results o...